Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy. prognosis and predictive factors
International Journal of Development Research
Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy. prognosis and predictive factors
Received 02nd January, 2021; Received in revised form 04th February, 2021; Accepted 19th March, 2021; Published online 22th April, 2021
Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled: “Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy. Prognosis and predictive factors” published by Light et al. in Ophthalmology Retina. (Doi.prg/1010161.oret.2020.11.010. Published on November 19, 2020), which assessed visual acuity and spectral domain optical coherence tomography outcomes in patients with retinal vein occlusion treated with anti-vascular endothelial growth factor agents demonstrating habitual corrected visual acuity of worse than 20/320 before any ocular therapy, with at least 6 months of follow-up. The authors concluded that a delay from symptom onset to first injection of 30 days or more portended higher incidence of incident sequelae (neovascular events or need for adjunct therapies). However, the validation, extrapolation, and generalizability of the authors’conclusion can be made only by statistical analyses including all the missing baseline factors mentioned by us in addition to the baseline characteristics already evaluated in this study, serving as potential prognosticators influencing anatomical and functional improvements after intravitreal injections of antangiogenic agents.
